Here you get to know about the Profile of Aurobindo Pharma Limited and the Products and Brands of the company. Aurobindo Pharma Within a short span of three decades, the company has emerged as the 10th largest global generic company, in terms of revenue.
Profile of Aurobindo Pharma
Aurobindo Pharma, commenced Operation in 1986 with a mission to become the most valued partner to the global pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products for patients in need.
- 22,000+ EMPLOYEES GLOBALLY
- 7 R&D CENTRES WITH A TEAM OF 1,600+ PROFESSIONALS
- 27 MANUFACTURING FACILITIES WORLDWIDE
Manufacturing Facilities In India
- 11 API AND INTERMEDIATE PLANTS
- 10 FORMULATION FACILITIES
- 5 R&D CENTRES
The company is the second-largest generic company in the US in terms of prescriptions dispensed and rank among the top 10 generic companies in eight out of the top of the 11 countries in Europe.
Financials of Aurobindo Pharma
- Total Sales: Rs 22,232 Cr
- Market Cap: 27,637 Cr.
- ROE: 19.01 %
- Sales Growth (3Yrs): 12.41 %
- Promoter holding: 51.87 %
- Debt to equity: 0.37
- Price to book value: 1.82
API Vertical Integration
Strategic in terms of vertical integration with 70% of API being sourced internally. As one of India’s largest vertically integrated pharmaceutical companies, strength the company lies in developing quality
- Active Pharmaceutical Ingredients (APIs) and
- Finished Dosage Forms (FDFs).
These products are manufactured across the company’s facilities, which have been inspected by various regulatory authorities such as the
- UK MHRA,
- Japan PMDA,
- Health Canada,
- MCC South Africa, and
- ANVISA Brazil.
The company has established in key therapeutic segments such as
- Central Nervous System (CNS),
- Cardiovascular System (CVS),
- Antibiotics, and
- Speciality Generics.
and the company also expanding presence in
- Respiratory and
- Oncology segments.
Raw material supply risks
Aurobindo’s dependency on the China market for import of raw material is high, and this may lead to a risk of import disruptions, short supplies and production bottlenecks due to environmental issues and unforeseen changes in government regulations and economic policies of China.
It is a challenge for the Company to ensure a regular and secure supply of raw materials required to produce products. For some raw materials, the Company has a single source of supply and alternative sources of supply may not be readily available. If the Company is unable to maintain good relationships with suppliers or find alternative suppliers on commercially acceptable terms, the financial condition, operations and profitability could be materially and adversely affected in the event of any supply shortage or disruption. A major portion of the Company’s raw material sourcing comes from China, and it is a concern for the Company.
Due to environmental controls in China, many Active Pharmaceutical Ingredients (API) and Key starting raw-material prices have increased. This was a major challenge for SCM, as it had to keep spending within the budget. The creation of a stable sourcing platform is a challenge and critical for the Company in material procurement, and the SCM team has taken steps in ensuring long-term supply sustainability in this space.